341 related articles for article (PubMed ID: 26433845)
1. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.
Spaccarelli N; Rook AH
Dermatol Clin; 2015 Oct; 33(4):731-45. PubMed ID: 26433845
[TBL] [Abstract][Full Text] [Related]
2. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
[TBL] [Abstract][Full Text] [Related]
3. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma.
Huen AO; Kim EJ
Dermatol Clin; 2015 Oct; 33(4):715-29. PubMed ID: 26433844
[TBL] [Abstract][Full Text] [Related]
4. Interferon in the treatment of cutaneous T-cell lymphoma.
Olsen EA; Bunn PA
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1089-107. PubMed ID: 8522486
[TBL] [Abstract][Full Text] [Related]
5. The treatment of mycosis fungoides.
Mestel DS; Beyer M; Steinhoff M; Sterry W; Assaf C
G Ital Dermatol Venereol; 2008 Dec; 143(6):395-408. PubMed ID: 19169212
[TBL] [Abstract][Full Text] [Related]
6. [Primary cutaneous lymphoma--mycosis fungoides].
Nagatani T; Okazawa H; Mizuno H; Yanagi N; Miyazawa M; Baba N
Gan To Kagaku Ryoho; 1997 Jan; 24(1):23-9. PubMed ID: 9020941
[TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatment for cutaneous lymphomas.
Mielke V; Staib G; Sterry W
Recent Results Cancer Res; 1995; 139():403-8. PubMed ID: 7597307
[TBL] [Abstract][Full Text] [Related]
9. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
[TBL] [Abstract][Full Text] [Related]
10. Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas.
Serri F; De Simone C; Venier A; Rusciani L; Marchetti F
Curr Probl Dermatol; 1990; 19():252-7. PubMed ID: 2404681
[No Abstract] [Full Text] [Related]
11. Juvenile mycosis fungoides with large-cell transformation: Successful treatment with psoralen with ultraviolet A light, interferon-alfa, and localized radiation.
Chan WH; Lewis DJ; Hinojosa T; Curry JL; Duvic M
Pediatr Dermatol; 2018 Jan; 35(1):e13-e16. PubMed ID: 29159918
[TBL] [Abstract][Full Text] [Related]
12. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
13. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma.
Nguyen CV; Bohjanen KA
Dermatol Clin; 2015 Oct; 33(4):683-96. PubMed ID: 26433841
[TBL] [Abstract][Full Text] [Related]
14. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK; Montanari F; Foss F; Reddy N
Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of combination therapies for mycosis fungoides.
Humme D; Nast A; Erdmann R; Vandersee S; Beyer M
Cancer Treat Rev; 2014 Sep; 40(8):927-33. PubMed ID: 24997678
[TBL] [Abstract][Full Text] [Related]
16. State of the art therapy of mycosis fungoides and Sézary syndrome.
Kemme DJ; Bunn PA
Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
[TBL] [Abstract][Full Text] [Related]
17. Combination of local PUVA-therapy and interferon alpha-2A in the treatment of tumoral stage mycosis fungoides.
Delpuget-Bertin N; Bernard P; Bedane C; Dang PM; Bonnetblanc JM
Dermatology; 1996; 193(1):74-5. PubMed ID: 8864634
[No Abstract] [Full Text] [Related]
18. Serum and tissue CTACK/CCL27 chemokine levels in early mycosis fungoides may be correlated with disease-free survival following treatment with interferon alfa and psoralen plus ultraviolet A therapy.
Goteri G; Rupoli S; Campanati A; Zizzi A; Picardi P; Cardelli M; Giantomassi F; Canafoglia L; Marchegiani F; Mozzicafreddo G; Brandozzi G; Stramazzotti D; Ganzetti G; Lisa R; Simonetti O; Offidani A; Federici I; Filosa G; Leoni P
Br J Dermatol; 2012 May; 166(5):948-52. PubMed ID: 22233400
[TBL] [Abstract][Full Text] [Related]
19. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
Dugas-Breit S; Schulze HJ; Hallermann C
J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome.
Kuzel TM; Roenigk HH; Samuelson E; Herrmann JJ; Hurria A; Rademaker AW; Rosen ST
J Clin Oncol; 1995 Jan; 13(1):257-63. PubMed ID: 7799028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]